DatChem Pty Ltd

DatChem has been established to commercialize DatChem-Breast and DatChem-Neuro. DatChem is the first technology to apply advanced data analytic techniques to patented applications of magnetic resonance spectroscopy. Importantly DatChem data is obtained on an installed MR scanner base and the data evaluated in the DatChem cloud. The first product to market is DatChem-Breast, which can quantify the risk of a woman developing breast cancer by applying its unique intelligence to predictive chemical signatures. It is integrated with the routine breast MRI. A twelve year blinded clinic trial of over 400 women has shown the technology correctly predicted 32 out of 32 women who would develop a breast cancer two to six years ahead of current methods. The clinic trial documentation was submitted to the United States Food and Drug Administration in April 2025 and is pending approval. If approved, this technology will allow women to make informed decisions as to their treatment. The next product to market will be DatChem-ADHD, which can provide the treating specialist with an objective diagnosis, identification of neurochemical pathways affected, and if and how the patient responds to therapy. A DatChem-ADHD test is provided at the same time as an MRI and will result in a neurochemical profile for each person. That profile will be compared to a clinical database of healthy brains and those with ADHD. The technology can be used to monitor response or lack thereof to therapy. Pain, post-traumatic stress disorder (PTSD), and blast exposure each have a unique neurochemical profile and can be objectively diagnosed. Again, response or lack of response to therapy can be monitored. For front line defenders, the technology can be applied to monitor resilience during training and in action. The technology for each of these applications has a granted patent or a PCT application pending. DatChem-Neuro is the only objective test available to date for each of these conditions.